切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2019, Vol. 08 ›› Issue (05) : 226 -229. doi: 10.3877/cma.j.issn.2095-3216.2019.05.007

所属专题: 文献

综述

组蛋白去乙酰化酶抑制剂与肾脏疾病
杜晓艳1, 冯宇颖2, 马良2,(), 付平2   
  1. 1. 610041 四川大学华西医院 临床药学部/药剂科
    2. 四川大学华西医院 肾内科
  • 收稿日期:2019-03-28 出版日期:2019-10-28
  • 通信作者: 马良
  • 基金资助:
    国家自然科学基金项目资助(81570668)

Histone deacetylase inhibitors and kidney diseases

Xiaoyan Du1, Yuying Feng2, Liang Ma2,(), Ping Fu2   

  1. 1. Department of Pharmacy; West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
    2. Department of Nephrology; West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2019-03-28 Published:2019-10-28
  • Corresponding author: Liang Ma
  • About author:
    Corresponding author: Ma Liang, Email:
引用本文:

杜晓艳, 冯宇颖, 马良, 付平. 组蛋白去乙酰化酶抑制剂与肾脏疾病[J]. 中华肾病研究电子杂志, 2019, 08(05): 226-229.

Xiaoyan Du, Yuying Feng, Liang Ma, Ping Fu. Histone deacetylase inhibitors and kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2019, 08(05): 226-229.

组蛋白去乙酰化是组蛋白表观遗传学修饰的重要的方式之一。组蛋白去乙酰化酶(HDACs)作为调控基因的关键蛋白,其功能异常早已被证实与肿瘤、神经退行性病变、肾脏病等发生和发展关系密切,进而推动HDAC抑制剂(HDACi)的研发及临床应用。本文综述HDACs在肾脏病发生发展中的作用及HDACi在肾脏病治疗中的应用前景。

Histone deacetylation is one of the important ways of epigenetic modification of histones. Histone deacetylases (HDACs), as key proteins in regulating genes, has long been confirmed to be closely related to the occurrence and development of tumors, neurodegenerative diseases, and kidney diseases, promoting the development and clinical application of HDAC inhibitors (HDACi). This article reviewed the role of HDACs in the development and progression of kidney diseases, as well as the application prospect of HDACi in the treatment of kidney diseases.

[1]
Jones PA, Ohtani H, Chakravarthy A, et al. Epigenetic therapy in immune-oncology [J]. Nat Rev Cancer, 2019, 19(3): 151-161.
[2]
Emmett MJ, Lazar MA. Integrative regulation of physiology by histone deacetylase 3 [J]. Nat Rev Mol Cell Biol, 2019, 20(2): 102-115.
[3]
Liang T, Fang H. Structure, functions and selective inhibitors of HDAC6 [J]. Curr Top Med Chem, 2018, 18(28): 2429-2447.
[4]
Batchu SN, Brijmohan AS, Advani A. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease [J]. Clin Sci, 2016, 130(12): 987-1003.
[5]
Kosciuk T, Wang M, Hong JY, et al. Updates on the epigenetic roles of sirtuins [J]. Curr Opin Chem Biol, 2019, 51: 18-29.
[6]
Sun L, Marin de Evsikova C, Bian K, et al. Programming and regulation of metabolic homeostasis by HDAC11 [J]. EBioMedicine, 2018, 33: 157-168.
[7]
Zupkovitz G, Lagger S, Martin D, et al. Histone deacetylase 1 expression is inversely correlated with age in the short-lived fish Nothobranchius furzeri [J]. Histochem Cell Biol, 2018, 150(3): 255-269.
[8]
Bacon T, Seiler C, Wolny M, et al. Histone deacetylase 3 indirectly modulates tubulin acetylation [J]. Biochem J, 2015, 472(3): 367-377.
[9]
Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy [J]. Cell, 2002, 110(4): 479-488.
[10]
Chen S, El-Dahr SS. Histone deacetylases in kidney development: implications for disease and therapy [J]. Pediatr Nephrol, 2013, 28(5): 689-698.
[11]
Qin HT, Li HQ, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives [J]. Expert Opin Ther Pat, 2017, 27(5): 621-636.
[12]
Shi Y, Xu L, Tang J, et al. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury [J]. Am J Physiol Renal Physiol, 2017, 312(3): F502-F515.
[13]
Tang J, Shi Y, Liu N, et al. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury [J]. Clin Sci, 2018, 132(3): 339-359.
[14]
Feng Y, Huang R, Guo F, et al. Selective histone deacetylase 6 inhibitor 23BB alleviated rhabdomyolysis-induced acute kidney injury by regulating endoplasmic reticulum stress and apoptosis [J]. Front Pharmacol, 2018, 9: 274.
[15]
Marumo T, Hishikawa K, Yoshikawa M, et al. Epigenetic regulation of BMP7 in the regenerative response to ischemia [J]. J Am Soc Nephrol, 2008, 19(7): 1311-1320.
[16]
Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury [J]. Nat Med, 2003, 9(7): 964-968.
[17]
Imai N, Hishikawa K, Marumo T, et al. Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury [J]. Stem Cells, 2007, 25(10): 2469-2475.
[18]
de Boer IH. A new chapter for diabetic kidney disease [J]. N Engl J Med, 2017, 377(9): 885-887.
[19]
Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney [J]. Nat Rev Nephrol, 2017, 13(10): 629-646.
[20]
Advani A, Huang Q, Thai K, et al. Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism [J]. Am J Pathol, 2011, 178(5): 2205-2214.
[21]
Gilbert RE, Huang Q, Thai K, et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor [J]. Kidney Int, 2011, 79(12): 1312-1321.
[22]
Noh H, Oh EY, Seo JY, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury [J]. Am J Physiol Renal Physiol, 2009, 297(3): F729-F739.
[23]
Tan AY, Zhang T, Michaeel A, et al. Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease [J]. J Am Soc Nephrol, 2018, 29(8): 2139-2156.
[24]
Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models [J]. Proc Natl Acad Sci USA, 2009, 106(51): 21819-21824.
[25]
Zhou X, Fan LX, Sweeney WE, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease [J]. J Clin Invest, 2013, 123(7): 3084-3098.
[26]
Li Y, Zhang X, Polakiewicz RD, et al. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization [J]. J Biol Chem, 2008, 283(19): 12686-12690.
[27]
Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy [J]. Am J Physiol Renal Physiol, 2009, 297(4): F996-F1005.
[28]
Choi SY, Piao ZH, Jin L, et al. Piceatannol attenuates renal fibrosis induced by unilateral ureteral obstruction via downregulation of histone deacetylase 4/5 or p38-MAPK signaling [J]. PLoS One, 2016, 11(11): e0167340.
[29]
Marumo T, Hishikawa K, Yoshikawa M, et al. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury [J]. Am J Physiol Renal Physiol, 2010, 298(1): F133-F141.
[30]
Van Beneden K, Geers C, Pauwels M, et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis [J]. Toxicol Applied Pharmacol, 2013, 271(2): 276-284.
[1] 王丽萍, 徐磊, 蒋天安, 强嘉璘. 微血管成像联合Qpack定量分析技术评估慢性肾脏病患者肾皮质区血流灌注的价值[J]. 中华医学超声杂志(电子版), 2023, 20(03): 292-296.
[2] 周川鹏, 杨浩, 魏微阳, 王奇, 黄亚强. 微创与标准通道经皮肾镜治疗肾结石合并肾功能不全的对比研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 470-475.
[3] 金艳盛, 董改琴, 李晓忠. 巨噬细胞在慢性肾脏病患者血管钙化中的作用与机制研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 234-237.
[4] 杨长沅, 凌曦淘, 丘伽美, 段若兰, 李琴, 林玉婕, 秦新东, 侯海晶, 卢富华, 苏国彬. 慢性肾脏病患者衰弱的筛查/评估工具研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 229-233.
[5] 李思佳, 苏晓乐, 王利华. 通过抑制Wnt/β-catenin信号通路延缓肾间质纤维化研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 224-228.
[6] 程庆砾. 新冠病毒感染与肾脏[J]. 中华肾病研究电子杂志, 2023, 12(04): 240-240.
[7] 王诗远, 张爱华. 慢性肾脏病相关认知障碍的发生机制研究进展[J]. 中华肾病研究电子杂志, 2023, 12(03): 163-167.
[8] 洪权. 从血管内皮探讨糖尿病肾病的进展机制[J]. 中华肾病研究电子杂志, 2023, 12(01): 60-60.
[9] 石晓璟, 苏晓乐, 王利华. 直接口服抗凝药在慢性肾脏病合并心房颤动患者中的应用[J]. 中华肾病研究电子杂志, 2023, 12(01): 26-31.
[10] 郑颖, 孟金铃, 蔡广研, 冯哲. 混合式教学模式在肾脏病学专业学位研究生循证医学课程中的实践与思考[J]. 中华肾病研究电子杂志, 2023, 12(01): 48-50.
[11] 黄梦杰, 孟金铃, 齐鹏, 苏亭予, 于茜, 吕强, 董哲毅, 冯哲. 肾脏内科住院医师规范化培训中科研能力的现状与思考[J]. 中华肾病研究电子杂志, 2023, 12(01): 51-53.
[12] 张瑞琪, 张丽娟, 孙斌. 甲状腺相关性眼病表观遗传学的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(04): 226-230.
[13] 易成, 韦伟, 赵宇亮. 急性肾脏病的概念沿革[J]. 中华临床医师杂志(电子版), 2023, 17(08): 906-910.
[14] 李昌艳, 顾芳, 刘娟, 唐明敏. 非布司他治疗慢性肾脏病伴发高尿酸血症的疗效及预后影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(03): 279-284.
[15] 黄晴, 赵瑞珩, 钱惠英. PCI-24781诱导SKOV-3细胞凋亡及相关机制的研究[J]. 中华临床医师杂志(电子版), 2022, 16(08): 775-781.
阅读次数
全文


摘要